Rapport Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview

Rapport Therapeutics

04/08/2025 14:21

Rapport Therapeutics Inc RAPP.OQ RAPP.O is expected to  show no change in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Rapport Therapeutics Inc is for a loss of 83 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Rapport Therapeutics Inc is $35.00, about 59.6% above its last closing price of $14.15

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.77
-0.76
-0.68
Beat
10.5
Dec. 31 2025
-0.63
-0.62
-0.57
Beat
8.8
Sep. 30 2024
-0.58
-0.58
-0.50
Beat
13.2​
Jun. 30 2024
-0.68
-0.68
-1.70
Missed
-151.7
​​
​

This summary was machine generated August 4 at 13:21 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)